Cabaletta Bio, Inc.
corporate_fare Company Profile
Cabaletta Bio, Inc. (NASDAQ:CABA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for CABA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-08, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for CABA spans 10-Q, 8-K, DEFA14A, 424B5.
Recent high-impact activity:
- Rese-cel Holds Immunomodulator-Free Responses at One Year Across Three Autoimmune Diseases
- Cabaletta Bio 10-Q: Going-Concern Warning Lifted as Cash Reaches $299.4M
- Cabaletta Extends Cash Runway Into 1Q28 With $299.4M, Starts Second Registrational Study
- Cabaletta Bio Secures $128.2M from Warrant Exercises, Addressing Going Concern
- Cabaletta Bio Q2 2026: $51M Net Loss, Going Concern Warning Despite $225M Cash
Financial Snapshot
Short Interest & Short Volume
8.19 days to coverFINRA reported short interest of 38,369,896 shares in CABA as of the October 30, 2026 settlement, a 2.3% decrease from the prior period — about 8.2 days to cover at its recent average daily volume. On November 20, 2026, 57.2% of CABA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.